Autres langues Verastem, Inc.

Actions

VSTM

US92337C2035

Temps réel estimé Cboe BZX Autres places de cotation 16:02:27 29/04/2024			Varia. 5j.	Varia. 1 janv.
9,525 ^USD	+1,55 %		-0,72 %	+18,80 %

18/04	Verastem Oncology annonce des changements à la direction	CI
14/03	Verastem, Inc. annonce ses résultats pour l'exercice terminé le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Verastem Names John Hayslip as Chief Medical Officer	18/04
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer	18/04
Verastem Oncology Announces Executive Changes	18/04
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	05/04
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer	18/03
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Verastem: Q4 Earnings Snapshot	14/03
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	14/03
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs	11/03
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation	05/03
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer	05/03
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	05/03
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024	05/03
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers	29/01
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers	29/01
Sector Update: Health Care Stocks Mixed Premarket Friday	19/01
Sector Update: Health Care	19/01
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer	19/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Verastem, Inc.

Actions

VSTM

US92337C2035

Autres langues

Filtres